LC
BBIO icon

Lindbrook Capital’s BridgeBio Pharma BBIO Stock Holding History

Lindbrook Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.74K Buy
195
+5
+3% +$169 ﹤0.01% 1829
2024
Q4 		$5.21K Sell
190
-41
-18% -$1.06K ﹤0.01% 1968
2024
Q3 		$5.88K Buy
231
+102
+79% +$2.68K ﹤0.01% 1950
2024
Q2 		$3.27K Sell
129
-367
-74% -$10K ﹤0.01% 2182
2024
Q1 		$15.3K Buy
496
+72
+17% +$2.45K ﹤0.01% 1351
2023
Q4 		$17.1K Buy
424
+321
+312% +$9.64K ﹤0.01% 1265
2023
Q3 		$2.72K Hold
103
– – ﹤0.01% 2012
2023
Q2 		$1.77K Hold
103
– – ﹤0.01% 2193
2023
Q1 		$1.71K Buy
103
+45
+78% +$525 ﹤0.01% 2306
2022
Q4 		$442 Sell
58
-111
-66% -$1.06K ﹤0.01% 2617
2022
Q3 		$2K Buy
169
+111
+191% +$1.15K ﹤0.01% 1993
2022
Q2 		$1K Sell
58
-453
-89% -$3.79K ﹤0.01% 2151
2022
Q1 		$5K Sell
511
-571
-53% -$5.86K ﹤0.01% 1570
2021
Q4 		$18K Buy
1,082
+1,057
+4,228% +$44.7K ﹤0.01% 1048
2021
Q3 		$1K Hold
25
– – ﹤0.01% 1678
2021
Q2 		$2K Hold
25
– – ﹤0.01% 1556
2021
Q1 		$2K Buy
+25
New +$1.64K ﹤0.01% 1519

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Lindbrook Capital's BBIO Position: Q1 2025 in Review

Lindbrook Capital increased its BridgeBio Pharma (BBIO) stake by 2.6% in Q1 2025, buying an estimated $169 and bringing the position to 195 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Lindbrook Capital first reported a position in BBIO in Q1 2021 and has held it in 17 quarters since. The position peaked at $18K in Q4 2021. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • Lindbrook Capital held 195 shares of BridgeBio Pharma worth $6.74K as of Q1 2025.
  • Lindbrook Capital bought 5 BridgeBio Pharma shares in Q1 2025, an estimated $169.
  • BridgeBio Pharma made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1829 holding.
  • Lindbrook Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 17 quarters since.
  • Lindbrook Capital's BridgeBio Pharma position peaked at $18K in Q4 2021.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.